Denkert C, Köbel M, Berger S, Siegert A, Leclere A, Trefzer U, Hauptmann S
Institute of Pathology, Charité Hospital, Berlin, Germany.
Cancer Res. 2001 Jan 1;61(1):303-8.
Cyclooxygenase (COX)-2 is an inducible enzyme involved in production of prostaglandins in inflammatory processes. There is now increasing evidence that a constitutive expression of COX-2 plays a role in development and progression of malignant epithelial tumors. In the present study we investigated expression and function of COX-2 in malignant melanoma. Expression of COX-2 was determined by immunohistochemistry in 28 cases of primary skin melanoma and 4 benign nevi. We show that COX-2 was expressed in 26 cases (93%) of melanomas, with a moderate to strong expression in 19 cases (68%). Benign nevi as well as normal epithelium were negative in all cases. A constitutive expression of COX-2 mRNA and protein was found in five melanoma cell lines (A375, MeWo, SK-Mel-13, SK-Mel-28, and IGR-37) by using Northern blot as well as immunoblotting. All melanoma cell lines produced prostaglandin (PG) E2 between 468 and 3500 pg/ml as determined by ELISA. Treatment with NS-398 (50 microM), a specific inhibitor of COX-2, suppressed PGE2 production of all melanoma cell lines by 50-96%. The IC50 for inhibition of PGE2 production by NS-398 was determined as 4 microM, indicating that NS-398 acts via inhibition of the COX-2 isoenzyme. We could show that proliferation of melanoma cell lines was not influenced by treatment with NS-398 in concentrations up to 100 microM. However, NS-398 reduced Matrigel invasion of all five malignant melanoma cell lines by 50-68%. Our results indicate that COX-2 is expressed in malignant melanomas and may be involved in regulation of melanoma invasion. It remains to be investigated whether selective inhibitors of COX-2 might be useful for prevention or treatment of malignant melanoma.
环氧化酶(COX)-2是一种诱导性酶,参与炎症过程中前列腺素的生成。现在越来越多的证据表明,COX-2的组成性表达在恶性上皮肿瘤的发生和发展中起作用。在本研究中,我们调查了COX-2在恶性黑色素瘤中的表达和功能。通过免疫组织化学法测定了28例原发性皮肤黑色素瘤和4例良性痣中COX-2的表达。我们发现,26例(93%)黑色素瘤中表达了COX-2,其中19例(68%)呈中度至强表达。所有病例中良性痣以及正常上皮均为阴性。通过Northern印迹法和免疫印迹法发现,五种黑色素瘤细胞系(A375、MeWo、SK-Mel-13、SK-Mel-28和IGR-37)中存在COX-2 mRNA和蛋白的组成性表达。通过酶联免疫吸附测定法(ELISA)测定,所有黑色素瘤细胞系产生的前列腺素(PG)E2在468至3500 pg/ml之间。用COX-2的特异性抑制剂NS-398(50 microM)处理后,所有黑色素瘤细胞系的PGE2产生量均降低了50%至96%。NS-398抑制PGE2产生的半数抑制浓度(IC50)测定为4 microM,表明NS-398通过抑制COX-2同工酶起作用。我们发现,浓度高达100 microM的NS-398处理对黑色素瘤细胞系的增殖没有影响。然而,NS-398使所有五种恶性黑色素瘤细胞系的基质胶侵袭能力降低了50%至68%。我们的结果表明,COX-2在恶性黑色素瘤中表达,可能参与黑色素瘤侵袭的调节。COX-2的选择性抑制剂是否可用于预防或治疗恶性黑色素瘤仍有待研究。